Literature DB >> 26622746

Transcatheter arterial chemoembolization as an examination method for hepatocellular carcinoma undetected by B-mode ultrasound, computed tomography and digital subtratcion angiography: A case report.

Zongquan Xu1, Chen Yu2, Shufang Wang1, Guohui Xu1.   

Abstract

Transcatheter arterial chemoembolization (TACE) is the conventional treatment for patients with unresectable hepatocellular carcinoma (HCC), but few studies to date have demonstrated the use of TACE as an examination method for uneasily detected HCC. The present study describes an unusual case of HCC with TACE as an examination method. A 41-year-old male presented with an elevated α-fetoprotein level (AFP) of 3,635 ng/ml, however, no tumor lesions were detected by B-mode ultrasound, computed tomography (CT) or digital subtraction angiography. During TACE treatment, two tumor lesions of ~0.5 and 0.8 cm were revealed in the right liver lobe, with no tumors in the left liver lobe. A month after TACE, a liver CT scan found 11 lesions (8 in the right liver lobe and 3 in the left liver lobe). The HCC patient's AFP levels decreased to an almost normal level following the TACE treatment. This study provokes consideration of the application of TACE in the diagnosis and treatment of HCC patients with liver lesions that are hard to detect by conventional means.

Entities:  

Keywords:  examination method; hepatocellular carcinoma; transcatheter arterial chemoembolization

Year:  2015        PMID: 26622746      PMCID: PMC4533667          DOI: 10.3892/ol.2015.3446

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  36 in total

Review 1.  Results of liver transplantation: with or without Milan criteria?

Authors:  Vincenzo Mazzaferro
Journal:  Liver Transpl       Date:  2007-11       Impact factor: 5.799

2.  Treatment strategies for hepatocellular carcinoma in Japan.

Authors:  Tatsuya Yamashita; Shuichi Kaneko
Journal:  Hepatol Res       Date:  2012-05-14       Impact factor: 4.288

3.  Small hepatocellular carcinoma. Detection with US, CT, MR imaging, DSA, and Lipiodol-CT.

Authors:  C Bartolozzi; R Lencioni; D Caramella; A Palla; A M Bassi; G Di Candio
Journal:  Acta Radiol       Date:  1996-01       Impact factor: 1.990

4.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

Review 5.  Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy.

Authors:  Augusto Villanueva; Beatriz Minguez; Alejandro Forner; Maria Reig; Josep M Llovet
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

6.  Comparison of resection and transarterial chemoembolisation in the treatment of advanced intrahepatic cholangiocarcinoma--a single-center experience.

Authors:  U Scheuermann; J M Kaths; M Heise; M B Pitton; A Weinmann; M Hoppe-Lotichius; G Otto
Journal:  Eur J Surg Oncol       Date:  2013-04-20       Impact factor: 4.424

Review 7.  Radiofrequency ablation for hepatocellular carcinoma.

Authors:  Hiroki Nishikawa; Toru Kimura; Ryuichi Kita; Yukio Osaki
Journal:  Int J Hyperthermia       Date:  2013-08-12       Impact factor: 3.914

Review 8.  Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies.

Authors:  Yun Ku Cho; Jae Kyun Kim; Mi Young Kim; Hyunchul Rhim; Joon Koo Han
Journal:  Hepatology       Date:  2009-02       Impact factor: 17.425

9.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

10.  Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study.

Authors:  Johannes Lammer; Katarina Malagari; Thomas Vogl; Frank Pilleul; Alban Denys; Anthony Watkinson; Michael Pitton; Geraldine Sergent; Thomas Pfammatter; Sylvain Terraz; Yves Benhamou; Yves Avajon; Thomas Gruenberger; Maria Pomoni; Herbert Langenberger; Marcus Schuchmann; Jerome Dumortier; Christian Mueller; Patrick Chevallier; Riccardo Lencioni
Journal:  Cardiovasc Intervent Radiol       Date:  2009-11-12       Impact factor: 2.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.